COMPANY OVERVIEW
Incorporated in PA in 2011, our MISSION is to translate our circulating cell-free DNA (cfDNA) in urine technology into improved cancer screening and management by liquid biopsy towards our VISION of decreased global cancer mortality.
Our proprietary technologies are in developing sensitive qPCR assays for tumor DNA markers using cfDNA in urine and blood, and robust methods for cfDNA isolation.
Our developments set out to change the way medicine is practiced by detecting primary and recurrent cancers and providing cancer genetics for personalized medicine in a noninvasive urine test. We collaborate with the leaders of biomarker research and clinical specialists to develop highly desired diagnostic/screening tools.
LATEST NEWS
| January 2023: Dr. Robert Gish joins JBS Science as a member of our Scientific Advisory board. Learn more
November 2022: JBS Science is pleased to announce two accepted abstracts, one poster and oral presentation, to the American Association for the Study of Liver Disease (AASLD) Liver Meeting 2022 including selection into the “Best of the Liver Meeting’s slide deck”. Learn more October 2022: JBS Science and collaborators awarded the Presidential Poster Award for work presented at American College of Gastroenterology Meeting 2022. Learn more September 2022 : JBS Science researchers will present at the International HBV Meeting 2022. Learn more February 2022: A Technology Commercialization Cooperation Agreement between Zinexts Life Science Corp. and JBS SCIENCE, INC. was signed to allow the non-exclusive manufacture and sale of the JBS nucleic isolation kits including cfDNA and RNA isolation kits by Zinexts. Zinexts is the OEM manufacturer of the JBS JPurX nucleic isolation instrument. This licensing agreement will facilitate the supply of JBS NA isolation kits for both the Zinexts and the JBS NA isolation automation platforms and for manual isolation kits. March 2020: JBS Science is launching cell-free nucleic acid purification system for liquid biopsy to market with the semi-automated JPurX-S200 system. Learn more April 2020: JBS Science scientists will present at the AACR Annual Meeting in San Diego, California.
September 2018: JBS Science is awarded $3 million Bridge Award by National Cancer Institute to commercialize a urine test for liver cancer screening. See full press release here. September 2018: JBS Science is pleased to announce the awarding of a Phase 2 SBIR grant from the National Human Genome Research Institute to develop a urine DNA Collection Kit. September 2016: JBS Science is pleased to announce the awarding of a Phase 1 SBIR grant from the National Cancer Institute to develop a urine DNA Kit for monitoring HCC recurrence. June 2016: JBS Science is selected to be one of 50 SBIR/STTR awardees to be showcased this year in the Innovation Zone at the upcoming BIO International Convention, this year in San Francisco, CA June 6-9, 2016. Join us at the Innovation Zone Booth #7253 and for an oral presentation on Tuesday, June 7 at 2:00 pm at the Personalized Medicine & Diagnostics Track in the West Presentation Theater 3. JBS Science is pleased to annouce an accepted abstract for ASCO. April 2016: JBS Science presents results at the AACR Annual Meeting 2016 in New Orleans. August 2015: JBS Science is pleased to announce the awarding of another Phase 1 SBIR grant from the National Human Genome Research Institute to develop a urine DNA collection kit. August 2013: JBS Science is pleased to announce the awarding of a Phase 2 SBIR from the National Cancer Institute to develop a urine test for the early detection of liver cancer. Sep 2012: JBS Science is pleased to announce the awarding of another Phase 1 SBIR grant from the National Cancer Institute to develop a urine test for colon cancer screening. June 2012: JBS Science is pleased to announce the awarding of Phase 1 SBIR grant from the National Cancer Institute to develop a urine test for the early detection of liver cancer. |